The antitumor mechanisms of aerobic exercise: A review of recent preclinical studies

Ningxin Jia1 | Yanan Zhou1 | Xiaosheng Dong2 | Meng Ding1

1College of Physical Education, Shandong Normal University, Jinan, China
2College of Physical Education, Shandong University, Jinan, China

Correspondence
Meng Ding, College of Physical Education, Shandong Normal University, 88 East Wenhua Road, Jinan, 250014, China.
Email: dingmeng@sdnu.edu.cn

Funding information
This review is supported by the Exercises Promote Health Theory and Practice Innovation Team of Shandong Normal University in China (No. 112/14001).

Abstract
Aerobic exercise is an important non-pharmacological means of antitumor intervention, but related mechanisms are poorly understood. In this review, previous studies are summarized from the aspects of tumor oxygenation, autophagy versus apoptosis, and organismal immunity. Current findings on the antitumor effects of aerobic exercise involve AMPK signaling, PI3K/Akt signaling, Th1/Th2 cytokine balance related to immunity, PD-1/PD-L1 immunosuppressive signaling, and related cytokine pathways. Several directions for further research are proposed, including whether newly discovered subgroups of cytokines influence the effects of aerobic exercise on tumors, tailoring corresponding exercise prescriptions based on the bidirectional effects of certain cytokines at different stages, identifying the potential effects of exercise time and intensity, and elucidating details of the unclear mechanisms. Through the discussion of the existing data, we hope to provide new ideas for the future research of exercise therapy.

KEYWORDS
aerobic exercise, antitumor, mechanism, signaling pathways

1 | BACKGROUND

Exercise is an important intervention for postoperative rehabilitation of oncology patients, and aerobic exercise is the main type of exercise intervention. The American College of Sports Medicine (ACSM) recommends that cancer survivors engage in at least 150–300 min/week of moderate intensity aerobic training.1 According to the cancer-specific exercise guideline, an effective exercise prescription that most consistently addresses health-related outcomes experienced due to a cancer diagnosis and cancer treatment includes moderate-intensity aerobic training at least three times per week, for at least 30 min, for at least 8–12 weeks.2 As an adjunctive therapy for postoperative rehabilitation of cancer patients, aerobic exercise has the effect of enhancing conventional cancer treatments.3,4 Available evidence suggests that aerobic exercise is associated with a reduction in tumor incidence, and has effects on affecting tumor physiology and controlling disease progression, which is associated with inhibition of tumor metastasis and recurrence.5,6 Aerobic exercise interventions during the treatment of patients with cancer have a significant impact on their survival, and patients’ higher aerobic fitness leads to longer estimated tumor doubling times.7 A 2018 study found that 6 months of moderate intensity aerobic exercise significantly improves the quality of life of oncology survivors.8 Another study found that the degree of participation in exercise was inversely associated with postmenopausal breast...
cancer incidence. Aerobic exercise produces changes in physiological characteristics and induces systemic alterations under adaptations to long-term training. Systemic effects of increased arterial pressure and cardiac output resulting from the rise in body temperature, as well as increased stroke volume and heart rate in response to acute exercise favor oxygen delivery, this effect can be further strengthened by the vascular remodeling induced by long-term aerobic training. Preclinical studies have shown that aerobic exercise has been shown to induce vascular normalization in mouse models, which indicates that aerobic exercise may affect local physiological responses and vascular adaptations in the tumor microenvironment.

However, despite the existence of corresponding clinical evidence for the beneficial effects of aerobic exercise on tumors, the mechanisms by which aerobic exercise inhibits or retards tumorigenesis currently remain elusive. On the basis of previous studies, we speculate that aerobic exercise may inhibit tumor development and progression by improving vascular oxygenation, modulating autophagy versus apoptosis, and affecting immune function, and then teased out the regulatory mechanisms and signaling pathways implicated in these processes. Finally, providing some ideas that are worth exploring for further discussion.

2 | MECHANISMS OF AEROBIC EXERCISE IN TUMOR HYPOXIA

2.1 | Hypoxic tumor microenvironment

Due to the swift proliferation of tumors during their growth, the diffusion of oxygen into the surrounding capillaries is unable to meet the demands posed by the continuous propagation of tumor cells, causing tissue hypoxia as well as metabolic imbalance and resulting in the formation of a hypoxic tumor environment (TME). Mitochondrial metabolic reprogramming is a dynamic process in tumorigenesis and development and is essential for tumor growth. Mitochondrial metabolism supports tumor anabolism by providing key metabolites for macromolecule synthesis and generating oncometabolites to maintain the cancer phenotype. The flexibility of mitochondrial metabolism may meet different needs during various stages of tumorigenesis to metastasis. Mitochondrial dysfunction and aerobic glycolysis (Warburg effect) have been widely accepted as tumor markers. In TME, inhibition of mitochondrial metabolism is crucial to switch from oxidative phosphorylation to glycolysis. Hypoxia is a common feature of many solid tumors and plays an important role in tumor initiation, progression, and metastasis. HIF (hypoxia-inducible factor) is a nuclear transcription factor that includes the members HIF-1, HIF-2, and HIF-3. HIF-1 is an important mediator in inducing aerobic glycolysis in tumor cells. HIF-1 expression is increased under hypoxia and activates adaptive transcriptional responses through related signaling pathways, which involves the upregulation of survival factors including angiogenic factors, regulating energy metabolism within tumor cells to adapt the tumor to a hypoxic TME and promote tumor cell metastasis and invasion. Angiogenesis is a condition for tumor cells to grow and metastasize, and vascular endothelial growth factor (VEGF) can promote endothelial cell growth and increase vascular permeability. Some studies have shown that under pathological conditions, HIF-1 induces the activation of multiple drug-resistance transporters by upregulating the protein expression of VEGF, leading to increased tumor malignancy. It has also been found that HIF-1α is associated with angiogenesis in non-small-cell lung cancer (NSCLC), and the expression of HIF-1α and VEGF are positively correlated and significantly higher in lung cancer tissues compared with normal tissues.

2.2 | Mechanisms of aerobic exercise on tumor perfusion and hypoxia

Exercise has the effect of regulating tumor vasculature and oxygenation, and it may lead to the development of relatively normal, more mature, and less permeable vessels in dysfunctional tumor vasculature. This blunted vasoreactivity may allow for maintenance or increased tumor perfusion during exercise. Aerobic exercise induces robust changes in mitochondrial content and quality that are shown to enhance mitochondrial biogenesis, and are shown to delay or prevent impairments in mitochondrial functions. Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) has been considered the master regulator of mitochondrial biogenesis. Acute aerobic exercise initiates a multitude of signals that activate PGC-1α, with the most widely accepted signals being: calcium/calmodulin-dependent protein kinase (CaMK), p38 mitogen-activated protein kinase (p38 MAPK), and AMP-activated protein kinase (AMPK) phosphorylation. By activating PGC-1α redox signaling pathways, aerobic exercise stimulates mitochondrial biogenesis, which in turn reduces the risk of carcinogenesis. Reactive oxygen species (ROS) is important components of the tumor growth environment. ROS in tumor cells is mainly generated from mitochondria, and mitochondrial ROS activate the HIF signaling pathway to mediate tumor cell metabolism. The activity of HIF-1 is regulated by hydroxylation. In hypoxia, the blockade of proline hydroxylation due to the inactivation of prolyl hydroxylase (PHD) and factor inhibiting HIF-1 (FIH-1) prevents the hydrolysis of HIF-1α, inducing activation of HIF-1 to affect the expression of
VEGF, which drives tumor cell proliferation. Increased shear stress on endothelial cells during aerobic exercise is associated with tumor vascular remodeling, prompting greater blood flow to the tumor. Aerobic exercise alleviates hypoxia by improving tumor perfusion volume, serves to reduce the accumulation of mitochondrial ROS, which favors HIF-1 inactivation. The pressure exerted on the vessel wall under acute exercise conditions increases with increasing exercise intensity, promoting the development of functionally mature vessels. Acute exercise increases tumor blood flow and decreases tumor vascular resistance, increasing tumor perfusion pressure in a murine prostate cancer (PCa) model, the increase in oxygen diffusion distance enables the hypoxic tumor area with restricted diffusion to shrink. The adaptation of tumor vascular structure to long-term exercise, can improve the oxygen delivery of peripheral tissue. Aerobic exercise exerts modulatory effects on tumor perfusion and hypoxia by enhancing acute and chronic oxygenation mechanisms in hypoxic tumor regions, which may help to delay tumor development (Figure 1).

2.3 Regulation of aerobic exercise on tumor brain metastasis

2.3.1 Hypoxia and tumor brain metastasis

Metastasis is driven by inflammatory signals and infiltration of inflammatory cells into the primary tumor. The key steps in the initiation and growth of tumor metastasis depend on the ability of tumor cells to transverse the vascular membrane, enter the bloodstream, and penetrate endothelial cells at new sites. Tumor cells have a propensity to metastasize under hypoxic conditions, and hypoxia downregulates the expression of adhesion molecules and increases tumor cell motility. In addition, Rho is a redox sensitive small GTPase whose activation is associated with destabilization and increased permeability of the endothelial barrier during tumorigenesis. Tight junction proteins are major structural components that determine paracellular integrity of brain endothelium, which regulates endothelial cell permeability, and creates a barrier, through cell adhesion, that limits access to the cerebrospinal fluid environment. Studies have found that an increase in blood–brain barrier permeability is accompanied by a decrease in the expression of tight junction proteins, whereas Rho kinase (ROCK), which is activated by RhoA GTPases, can induce phosphorylation of tight junction proteins, leading to their disruption and promoting the migration of monocytes through the blood–brain barrier. Tumor cells can interfere with the expression of tight junction proteins and extravasate and spread into the brain between disrupted tight junction proteins. Hypoxia causes the degradation of tight junction proteins, which further increases blood–brain barrier permeability. Redox-sensitive small GTPases are involved in blood–brain barrier remodeling and barrier disruption, disrupts the structure of tight junction proteins, leading to tumor cell extravasation.

FIGURE 1 Mechanisms of aerobic exercise regulate tumor perfusion and hypoxia
2.3.2 | Mechanisms of vascular permeability to aerobic exercise

The redox stability of brain endothelial cells may protect the brain against tumor metastasis.\(^5\)\(^9\) Aerobic exercise maintains or increases the expression of tight junction proteins by regulating the activity of redox sensitive small GTPases, thereby affecting the oxidative status and redox sensitive signaling of cerebral microvessels to maintain blood–brain barrier integrity.\(^5\)\(^0\) An animal study found that at the early stage of tumor growth, the activation of RhoA in the microvessels of exercising mice was relatively low and the expression of tight junction proteins remained unchanged.\(^5\)\(^0\) In addition, aerobic exercise promotes VEGF expression in hippocampal tissue by inducing the proliferation of new vessels, and inducing peripheral tissue VEGF to cross the blood–brain barrier to promote angiogenesis, which further increases vessel density.\(^5\)\(^1\)

3 | MECHANISMS OF AEROBIC EXERCISE ON AUTOPHAGY

AMPK maintains and regulates cellular energy metabolism, which is closely related to the occurrence and development of cancer cells.\(^5\)\(^2\) AMPK acts as a tumor suppressor early in the disease course by inhibiting mammalian target of rapamycin (mTOR), inducing cell autophagy to regulate tumor growth,\(^5\)\(^3\) mTOR is a central protein that inhibits cell autophagy, and has a negative regulatory effect on the autophagy core gene ULK1.\(^5\)\(^4\) The AMPK/mTOR pathway is associated with cell autophagy, and when AMP/ATP levels increase, inhibit downstream mTOR protein function by activated AMPK induces autophagy to occur.\(^5\)\(^5\) AMPK can also promote cell autophagy by activating ULK1 through direct phosphorylation.\(^5\)\(^6\) Studies showed that promoting cytotoxic autophagy is able to inhibit the growth of breast cancer cells, by activating AMPK/ULK1 signaling axis.\(^5\)\(^7\) However, this characteristic of AMPK in turn leads to the drug resistance in later stages of tumors.

AMPK has a bidirectional effect on tumor growth, which is related to energy metabolism in the TME.\(^5\)\(^8\) AMPK is significantly activated under oncogenic stress conditions, promoting glucose metabolism and angiogenesis in tumor cells.\(^5\)\(^9\) Knockout of AMPK in animal experiments was found to inhibit tumor growth, especially in preneoplastic lesions.\(^6\)\(^0\) Thus, inhibiting AMPK with effective interventions at early tumor stages may delay tumor development. However, conversely, AMPK activity is low during energy sufficiency. As a negative regulator of the Warburg effect, AMPK inhibits tumor growth by regulating glycolysis and lipogenesis of tumor cells through regulating HIF-1α, while the loss of AMPK can promote tumorigenesis by regulating lipid metabolism.\(^5\)\(^1\)

Exercise is one of the factors that activate AMPK, and low to moderate intensity aerobic exercise can significantly enhance the activity of AMPK.\(^6\)\(^2\) Liver kinase B1 (LKB1) inhibits mTOR by activating AMPK under low ATP conditions, and the depletion of large amounts of ATP during exercise elevates the AMP/ATP ratio and activates AMPK mediated by LKB1.\(^6\)\(^3\),\(^6\)\(^4\) VEGF is able to promote angiogenesis by modulating cellular metabolism through the activation of the AMPK signaling pathway under conditions of Ca\(^2+\)/calmodulin-dependent protein kinase (CaMKK-β) phosphorylation in normal conditions.\(^6\)\(^5\) While under pathological conditions, stimulation of hypoxia in TME also activates AMPK, which inhibits the expression of multiple angiogenic factors.\(^6\)\(^6\) Aerobic exercise requires oxygen and constant energy consumption, which activates AMPK to promote angiogenesis in normal cells to exert protective effects through the AMPK/Akt/mTOR signaling pathway\(^6\)\(^7\) while blocking tumor cell metastasis under pathological conditions. Similar to its role in tumor metastasis, the antiangiogenic effects of AMPK are mostly dependent on the activation of upstream kinase LKB1 and CaMKK-β.\(^6\)\(^8\) Considering the characteristic of AMPK, it is recommended that patients undergo aerobic exercise intervention at the initial stage of tumorigenesis such that the cellular autophagic activity of AMPK is exerted to inhibit tumor growth and metastasis (Figure 2).

4 | MECHANISMS OF AEROBIC EXERCISE ON APOPTOSIS

Tumor cells are characterized by resistance to anoikis, the PI3K/Akt signaling pathway is associated with anoikis resistance.\(^6\)\(^9\) Insulin and insulin-like growth factors (IGFs) stimulate nutrient uptake by tumor cells through the PI3K/Akt/mTOR signaling pathway to promote proliferation.\(^7\) Akt is associated with the anoikis resistance of tumor cells, activated Akt increases the motility of tumor cells.\(^7\)\(^1\) AMPK, when activated by LKB1, can promote anoikis and thereby inhibit tumor metastasis.\(^7\)\(^2\) Aerobic exercise decreases circulating levels of insulin, IGF1, and leptin, which is accompanied by altered metabolic signaling in tumor cells, as shown by increased AMPK activation and decreased levels of activated PI3K, Akt, and mTOR,\(^7\)\(^3\),\(^7\)\(^4\) inhibits aerobic glycolysis in cancer cells and induces tumor cell apoptosis (Figure 2).

5 | MECHANISMS OF AEROBIC EXERCISE ON IMMUNE FUNCTION

5.1 | Specific immunity

The PD-1/PD-L1 signaling pathway is an important component of tumor immunosuppression. T cells are
potent immune cells against solid tumors, while PD-1 inhibits downstream PI3K/Akt signals and induces T-cell apoptosis.\textsuperscript{75} PD-L1 causes T-cell exhaustion and generates immune tolerance, which contributes to tumor immune escape.\textsuperscript{76} Animal experiments showed that the inhibition of CD8\textsuperscript{+}T cells causes cancer development.\textsuperscript{77} TME induces the massive generation of regulatory T cells (Treg cells), which inhibit the function of effector T cells.\textsuperscript{78} FoxP3 is an important marker for Treg cells, and the expression of FoxP3\textsuperscript{+}Treg is associated with the immune escape of tumor cells, while HIF-1\textalpha can upregulate molecules that attract FoxP3\textsuperscript{+}Treg.\textsuperscript{79,80} CD4\textsuperscript{+}FoxP3\textsuperscript{+}Treg cells are responsible for inducing dominant immune tolerance to tumors,\textsuperscript{81} determined by the ratio between CD8\textsuperscript{+}T cells and FoxP3\textsuperscript{+}Treg cells.\textsuperscript{82} A relatively high number of FoxP3\textsuperscript{+}Treg cells results in a lower ratio, which is significantly associated with shorter overall survival in most solid tumors.\textsuperscript{83} Aerobic exercise is able to increase the effective perfusion of tumor cells, and leads to a faster degradation of HIF-1\textalpha and inhibits FoxP3\textsuperscript{+}Treg recruitment.\textsuperscript{84,85} Studies on tumor-infiltrating B cells have linked cellular immunity and humoral immunity in solid tumors.\textsuperscript{86} Increased antigen presentation by B cells to CD4\textsuperscript{+}T cells in the TME, in combination with anti-PD-1 therapy, may further enhance immune responses.\textsuperscript{87} However, most studies on immune regulation mediated by tumor-infiltrating B cells have been performed in vitro, and the mechanism is not well defined. Further studies are therefore needed.

### 5.2 Nonspecific immunity

Activated macrophages can be divided into two types: M1 and M2 macrophages, involved in tumor immune responses.\textsuperscript{88} Inflammatory cytokines released by macrophages can promote the proliferation of tumor cells.\textsuperscript{89} Recent studies showed that tumor necrosis factor-\textalpha (TNF-\textalpha) secreted by macrophages and the inflammatory cytokine interleukin-1\beta (IL-1\beta) induce the upregulated expression of PD-L1 via NF-kB and STAT3 signaling.
pathways in tumor cells. Interleukin-6 (IL-6) is an immune inflammatory cytokine, and the effects on the inflammatory response depend on the context. IL-6 enhances inflammatory immune function in normal conditions, while inhibiting the expression of TNF-α under hypoxia, leading to anti-inflammatory effects. In pathological settings, IL-6 induces macrophage polarization from M1 to M2, causing tumor cell metastasis. M2 promotes proliferation by regulating PD-L1 expression. Due to the lactate-sensitive property, macrophages are activated into M2 in lactate-rich TME. Aerobic exercise promotes activation of the M1, improving oxygenation to reduce the exposure to lactate, thereby enhancing M1 activation or decreasing the activation of M2. Moreover, epinephrine surges during aerobic exercise, mobilizing NK cells into the circulation to inhibit tumor growth. However, with new classification of different M2 subgroups, whether aerobic exercise will continue this shift is worth investigating in the future (Figure 2).

6 CONCLUSION

Aerobic exercise acts as a tumor suppressor with regard to processes occurring in the hypoxic tumor microenvironment, cell autophagy versus apoptosis, and body immune function through regulation of the corresponding mechanisms and triggering certain cytokine signaling pathways. Some new ideas deserve continued exploration: determining whether newly discovered subgroups of cytokines influence the positive effects of aerobic exercise on tumors; adjusting corresponding exercise prescriptions based on the bidirectional effects of certain cytokines at different lesion stages; identifying the potential effects of exercise time and intensity on tumor growth. The study of the link between aerobic exercise and tumors still needs further exploration in the future, so as to develop more effective clinical treatment regimens.

CONFLICT OF INTEREST

No conflict of interest in this study.

AUTHOR CONTRIBUTIONS

NJ and MD planned the structure of the manuscript. NJ wrote the manuscript and designed the figures. YZ and XD participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

ETHICAL STATEMENT

This is a review article and the need for ethics approval and consent was waived.

DATA AVAILABILITY STATEMENT

This is a review article. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. All the figures in the manuscript are original.

ORCID

Ningxin Jia https://orcid.org/0000-0003-3655-1018

REFERENCES

1. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451-1462.
2. Campbell KL, Winters-stone KM, Wiskemann J, et al. Exercise Guidelines for Cancer Survivors: consensus statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019;51(11):2375-2390.
3. Wiggins JM, Opoku-Acheampong AB, Baumfalk DR, Siemann DW, Behnake BJ. Exercise and the tumor microenvironment: potential therapeutic implications. Exerc Sport Sci Rev. 2018;46(1):56-64.
4. Garcia E, Becker VGC, McCullah DJ, et al. Blood flow responses to mild-intensity exercise in ectopic vs. orthotopic prostate tumors; dependence upon host tissue hemodynamics and vascular reactivity. J Appl Physiol. 2016;121(1):15-24.
5. Hojman P, Gehl J, Christensen JF, Pedersen BK. Molecular mechanisms linking exercise to cancer prevention and treatment. Cell Metab. 2018;27(1):10:21.
6. Cormie P, Zopf EM, Zhang X, Schmitz KH. The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiol Rev. 2017;39(1):71-92.
7. Hagar A, Flynn S, Patterson K, Haddad F. Muscular endurance and progression rates of early-stage invasive ductal carcinoma: a pilot study. Breast J. 2018;24(5):849-851.
8. Brown JC, Damjanov N, Courneya KS, et al. A randomized dose-response trial of aerobic exercise and health-related quality of life in colon cancer survivors. Psycho-Oncol. 2018;27(4):1221-1228.
9. Bellocco R, Marrone G, Ye W, et al. A prospective cohort study of the combined effects of physical activity and anthropometric measures on the risk of post-menopausal breast cancer. Eur J Epidemiol. 2016;31(4):395-404.
10. Hawley JA, Hargreaves M, Joyner MJ, Zierath JR. Integrative biology of exercise. Cell. 2014;159(4):738-749.
11. Schumacher O, Galvão DA, Taaffe DR, Chee R, Spry N, Newton RU. Exercise modulation of tumour perfusion and hypoxia to improve radiotherapy response in prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(1):1-14.
12. Betof AS, Lascola CD, Weitzel D, et al. Modulation ofmurine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. J Natl Cancer Inst. 2015;107(5):djv040.
13. Yang G, Shi R, Zhang Q. Hypoxia and oxygen-sensing signaling in gene regulation and cancer progression. Int J Mol Sci. 2020;21(21):8162.
14. Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368:6487.
15. Vasan K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. Cell Metab. 2020;32(3):341-352.
16. El Hout M, Cosiallows E, Mehroum P, Hamai A. Crosstalk between autophagy and metabolic regulation of cancer stem cells. *Mol Cancer*. 2020;19(1):27.

17. Koelwyn GJ, Quail DF, Zhang X, White RM, Jones LW. Exercise-dependent regulation of the tumour microenvironment. *Nat Rev Cancer*. 2017;17(10):620-632.

18. Liu Z-J, Semenza GL, Zhang H-F. Hypoxia-inducible factor 1 and breast cancer metastasis. *J Zhejiang Univ-Sci B*. 2015;16(1):32-43.

19. Balamurugan A. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. *Int J Cancer*. 2016;138(5):1058-1066.

20. Choudhry H, Harris AL. Advances in hypoxia-inducible factor biology. *Cell Metab*. 2018;27(2):281-298.

21. Harada H. Hypoxia-inducible factor 1-mediated characteristic features of cancer cells for tumor radioresistance. *J Radiat Res*. 2016;57:199-1105.

22. Fei M, Guan J, Xue T, et al. Hypoxia promotes the migration and invasion of human hepatocarcinoma cells through the HIF-1 alpha-IL-8-Akt axis. *Cell Mol Biol Lett*. 2018;23:46.

23. Chung C. From oxygen sensing to angiogenesis: targeting the hypoxia signaling pathway in metastatic kidney cancer. *Am J Health-Syst Pharm*. 2020;77(24):2064-2073.

24. Chappell JC, Payne LB, Rathmell WK. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. *J Clin Invest*. 2019;129(2):442-451.

25. Lu Q-L, Liu J, Zhu X-L, Xu W-J. Expression of nerve growth factor and hypoxia inducible factor-1 alpha and its correlation with angiogenesis in non-small cell lung cancer. *J Huazhong Univ Sci Technol-Med Sci*. 2014;34(3):359-362.

26. Meinild Lundby ÅK, Jacobs RA, Gehrig S, et al. Exercise training increases skeletal muscle mitochondrial volume density by enlargement of existing mitochondria and not de novo biogenesis. *Acta Physiol (Oxf)*. 2018;222(1):e12976.

27. Dumont S, Le Pennec S, Donnart A, et al. Transcriptional orchestration of mitochondrial homeostasis in a cellular model of PGC-1-related coactivator-dependent thyroid tumor. *Oncotarget*. 2018;9(22):15883-15894.

28. Memme JM, Erlich AT, Phukan G, Hood DA. Exercise and mitochondrial health. *J Physiol*. 2021;599(3):803-817.

29. Druck T, Cheung DG, Park D, et al. Phlt-Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells. *Cell Death Dis*. 2019;10(3):147.

30. Liao Z, Chua D, Tan NS. Reactive oxygen species: a volatile driver of field cancerization and metastasis. *Mol Cancer*. 2019;18(1):65.

31. Weng M-S, Chang J-H, Hung W-Y, Yang Y-C, Chien M-H. The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance. *J Exp Clin Cancer Res*. 2018;37(1):61.

32. Luo W, Wang Y. Hypoxia mediates tumor malignancy and therapy resistance. Hypoxia and cancer metastasis. *Adv Exp Med Biol*. 2019;1136:1-18.

33. Tirpe AA, Gulei D, Ciortea SM, Crivii C, Hypoxia B-N. Overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. *Int J Mol Sci*. 2019;20(24):6140.

34. Zhang T, Suo C, Zheng C, Zhang H. Hypoxia and metabolism in metastasis. Hypoxia and cancer metastasis. *Adv Exp Med Biol*. 2019;1136:87-95.

35. Schadler KL, Thomas NJ, Galie PA, et al. Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy. *Oncotarget*. 2016;7(40):65429-65440.

36. Kopp R, Koebitzl L, Egg M, Pelster B. HIF signaling and overall gene expression changes during hypoxia and prolonged exercise differ considerably. *Physiol Genomics*. 2011;43(9):506-516.

37. Di Meo S, Napolitano G, Venditti P. Mediators of physical activity protection against ROS-linked skeletal muscle damage. *Int J Mol Sci*. 2019;20(12):3024.

38. Hagar A, Wang Z, Koyama S, et al. Endurance training slows breast tumor growth in mice by suppressing Treg cells recruitment to tumors. *BMC Cancer*. 2019;19(1):536.

39. Smith HA, Kang Y. The metastasis-promoting roles of tumor-associated immune cells. *J Mol Med-Imm*. 2013;91(4):411-429.

40. Wolff G, Toborek M. Targeting the therapeutic effects of exercise on redox-sensitive mechanisms in the vascular endothelium during tumor progression. *IUBMB Life*. 2013;65(7):565-571.

41. Hong S-H, Tilan JU, Galli S, et al. In vivo model for testing effect of hypoxia on tumor metastasis. *Jove-J Vis Exp*. 2016;118:54532.

42. Koziel MJ, Kowalska K, Claudins P-C. Claudins: New Players in Human Fertility and Reproductive System Cancers. *Cancers (Basel)*. 2020;12(3):711.

43. Tabariès S, Siegel PM. The role of claudins in cancer metastasis. *Oncoogene*. 2017;36(9):1176-1190.

44. Corrigan F, Mander KA, Leonard AV, Vink R. Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation. *J Neuroinflammation*. 2016;13(1):264.

45. Jia W, Lu R, Martin TA, Jiang WG. The role of claudin-5 in blood-brain barrier (BBB) and brain metastases (Review). *Mol Med Rep*. 2014;9(3):779-785.

46. Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. *Small GTPases*. 2014;5(2):e29846.

47. Feng S-R, Chen Z-X, Cen J-N, Shen H-J, Wang Y-Y, Yao L. Disruption of blood brain-barrier by leukemic cells in central nervous system leukemia. *Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi*. 2011;32(5):289-293.

48. Aghajanian A, Wittchen ES, Campbell SL, Burridge K. Direct activation of RhoA by reactive oxygen species requires a redox-sensitive Motif. *PLoS One*. 2009;4(11):e8045.

49. Wolff G, Balke JE, Andras IE, Park M, Toborek M. Exercise modulates redox-sensitive small GTPase activity in the brain microvasculature in a model of brain metastasis formation. *PLoS One*. 2014;9(5):e97033.

50. Wolff G, Davidson SJ, Wrobel JK, Toborek M. Exercise maintains blood-brain barrier integrity during early stages of brain metastasis formation. *Biochem Biophys Res Comm*. 2015;463(4):811-817.

51. Morland C, Andersson KA, Haugen ØP, et al. Exercise induces cerebral VEGF and angiogenesis via the lactate receptor HCAR1. *Nature Commun*. 2017;8:15557.

52. Carling D. AMPK signalling in health and disease. *Curr Opin Cell Biol*. 2017;45:31-37.

53. Tripathi DN, Chowdhury R, Trudel LJ, et al. Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. *Proc Natl Acad Sci*. 2013;110(32):E2950-E2957.

54. Yuan J, Zhao X, Hu Y, et al. Autophagy regulates the degeneration of the auditory cortex through the AMPK-mTOR-ULK1 signaling pathway. *Int J Mol Med*. 2018;41(4):2086-2098.

55. Yamamoto T, Takahatake Y, Kimura T, et al. Time-dependent dysregulation of autophagy: Implications in aging and
mitochondrial homeostasis in the kidney proximal tubule. *Autophagy*. 2016;12(5):801-813.

56. Wang L, Yuan D, Zheng J, et al. Chikusetsu saponin IVa attenuates isoprenaline-induced myocardial fibrosis in mice through activation autophagy mediated by AMPK/mTOR/ULK1 signaling. *Phytomedicine*. 2019;58:152764.

57. Chung SJ, Nagaraju GP, Nagalingam A, et al. ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis. *Autophagy*. 2017;13(8):1386-1403.

58. Hardie DG. Molecular pathways: is AMPK a friend or a foe in cancer? *Clin Cancer Res*. 2015;21(17):3836-3840.

59. Chhipa RR, Fan Q, Anderson J, et al. AMP kinase promotes glioblastoma bioenergetics and tumour growth. *Nat Cell Biol*. 2018;20(7):823-835.

60. Eichner LJ, Brun SN, Herzig S, et al. Genetic analysis reveals AMPK is required to support tumor growth in murine Kras-dependent lung cancer models. *Cell Metab*. 2019;29(2):285-302.e7.

61. Faubert B, Boily G, Izreig S, et al. AMPK is a negative regulator of the warburg effect and suppresses tumour growth in vivo. *Cell Metab*. 2013;17(1):113-124.

62. Diniz TA, Aquino Júnior JCJ, Mosele FC, et al. Exercise-induced AMPK activation and IL-6 muscle production are disturbed in adiponectin knockout mice. *Cytokine*. 2019;119:71-80.

63. Ok DP, Ko K, Bae JY. Exercise without dietary changes alleviates nonalcoholic fatty liver disease without weight loss benefits. *Lipids Health Dis*. 2018;17(1):207.

64. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. *Cancer Cell*. 2004;6(1):91-99.

65. Doménech E, Maestre C, Esteban-Martinez L, et al. AMPK and its the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis. *PloS One*. 2013;8(1):e52852.

66. Liang P, Jiang B, Li Y, et al. Autophagy promotes angiogenesis via AMPK/Akt/mTOR signaling during the recovery of heat-denatured endothelial. *Cell Death Dis*. 2018;9(12):1152.

67. Stahmann N, Woods A, Spengler K, et al. Activation of AMP-activated protein kinase by vascular endothelial growth factor mediates endothelial angiogenesis independently of nitric-oxide synthase. *J Biol Chem*. 2010;285(14):10638-10652.

68. Edirweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. *Semin Cancer Biol*. 2019;59:147-160.

69. Belardi V, Gallagher EJ, Novosyadlyy R, LeRoith D. Insulin and IGFs in obesity-related breast cancer. *J Mammary Gland Biol Neoplasia*. 2013;18(3-4):277-289.

70. Kasprzak A, Kwasniewski W, Adamek A, Gozdzicka-Jozefiak A. Insulin-like growth factor (IGF) axis in carcinogenesis. *Mutation Res-Res Mutat Res*. 2017;772:78-104.

71. Jin L, Chun J, Pan C, et al. The PLAG1-GDH1 axis promotes anoikis resistance and tumor metastasis through CamKK2-AMPK signaling in LKB1-deficient lung cancer. *Mol Cell*. 2018;69(1):87-99.e7.

72. Zhu Z, Jiang W, Sells JL, Neil ES, McGinley JN, Thompson HJ. Effect of nonmotorized wheel running on mammary carcinogenesis: circulating biomarkers, cellular processes, and molecular mechanisms in rats. *Cancer Epidemiol Biomark Prev*. 2008;17(8):1920-1929.

73. Xie L, Jiang YU, Ouyang P, et al. Effects of dietary calorie restriction or exercise on the PI3K and ras signaling pathways in the skin of mice. *J Biol Chem*. 2007;282(38):28025-28035.

74. Hofmeyer KA, Jeon H, Zang X. The PD-1/PD-L1 (B7–H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. *J Biomed Biotechnol*. 2011;2011:451694.

75. Deng X, Xiong F, Li X, et al. Application of atomic force microscopy in cancer research. *J Nanobiotechnol*. 2018;16(1):102.

76. Ananth AA, Tai L-H, Lassell C, et al. Surgical stress abrogates pre-existing protective T cell mediated anti-tumor immunity leading to postoperative cancer recurrence. *PLoS One*. 2016;11(5):e0155947.

77. Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? *Cancer Sci*. 2019;110(7):2080-2089.

78. Di S, Fan C, Ma Z, et al. PERK/eIF-2alpha/CHOP signaling pathway dependent ROS generation mediates butein-induced non-small-cell lung cancer apoptosis and G2/M phase arrest. *Int J Biol Sci*. 2019;15(8):1637-1653.

79. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. *Cell Metab*. 2016;23(1):27-47.

80. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25(+)CD4(+) T cells: a common basis between tumor immunity and autoimmunity. *J Immunol*. 1999;163(10):5211-5218.

81. Chaudhary B, Ellord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. *Vaccines*. 2016;4(3):28.

82. Facciabene A, Motz GT, Coukos G. T regulatory cells: key players in tumor immune escape and angiogenesis. *Can Res*. 2012;72(9):2162-2171.

83. Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. *Nature*. 2011;475(7355):226–230.

84. Ren L, Yu Y, Wang L, Zhu Z, Lu R, Yao Z. Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer. *Oncotarget*. 2016;7(46):75763-75773.

85. Bruno TC, Ebner PJ, Moore BL, et al. Antigen-presenting intratumoral B cells affect CD4(+) TIL phenotypes in non-small-cell lung cancer patients. *Cancer Immunol Res*. 2017;5(10):898-907.

86. Seto T, Sam D, Pan M. Mechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer. *Med Sci*. 2019;7(2):14.

87. Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. *Nat Rev Cancer*. 2016;16(7):447-462.

88. Zhou Y, Xia L, Liu Q, et al. Induction of pro-inflammatory response via activated macrophage-mediated NF-kappa B and STAT3 pathways in gastric cancer cells. *Cell Physiol Biochem*. 2018;47(4):1399-1410.

89. Chen J, Li G, Meng H, et al. Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. *Cancer Immunol Immunother*. 2012;61(1):101-108.

90. Pedersen BK, Febrario MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. *Nature Rev Endocrinol*. 2012;8(8):457-465.

91. Ju X, Zhang H, Zhou Z, Chen M, Wang Q. Tumor-associated macrophages induce PD-L1 expression in gastric
cancer cells through IL-6 and TNF-alpha signaling. Exp Cell Res. 2020;396(2):112315.

93. Carmona-Fontaine C, Deforet M, Akkari L, Thompson CB, Joyce JA, Xavier JB. Metabolic origins of spatial organization in the tumor microenvironment. Proc Natl Acad Sci USA. 2017;114(11):2934-2939.

94. Abdalla DR, Rocha Aleixo AA, Murta EFC, Michelin MA. Innate immune response adaptation in mice subjected to administration of DMBA and physical activity. Oncol Lett. 2014;7(3):886-890.

95. Dimitrov S, Lange T, Born J. Selective mobilization of cytotoxic leukocytes by epinephrine. J Immunol. 2010;184(1):503-511.

96. Pedersen L, Idorn M, Olofsson G, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 2016;23(3):554-562.

97. Bai J, Adriani G, Dang TM, et al. Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and beta-2 integrin interactions. Oncotarget. 2015;6(28):25295-25307.

How to cite this article: Jia N, Zhou Y, Dong X, Ding M. The antitumor mechanisms of aerobic exercise: A review of recent preclinical studies. Cancer Med. 2021;10:6365–6373. https://doi.org/10.1002/cam4.4169